Drug Profile
GTB 3550
Alternative Names: 161533 TriKE; cam16-IL15-camB7H3; CD16/IL-15/CD33 - Oxis Biotech; CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes); GTB-3550; GTB-3550 TriKE™; OXIS3550; OXS-3550; OXS-3550-TriKELatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer Oxis Biotech; University of Minnesota
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoglobulin fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes; Systemic mastocytosis
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 21 Mar 2022 GT Biopharma terminates phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral) (NCT03214666)
- 21 Mar 2022 GT Biopharma terminates phase I/II trial in Myelodysplastic syndromes (Second-line therapy or greater) in USA (Parenteral) (NCT03214666)